Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On December 27, 2024, Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Frequently asked questions
What sector does Biora Therapeutics Inc (BIOR) operate in?
Biora Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Biora Therapeutics Inc (BIOR) current stock price?
As of the latest data, Biora Therapeutics Inc stock price is $0.22, with a previous close of $0.22.
What is Biora Therapeutics Inc (BIOR) current market capitalization?
Biora Therapeutics Inc market cap is approximately 994.99 thousand.
What is Biora Therapeutics Inc (BIOR) Earnings Per Share (EPS)?
The trailing EPS is $0.36, and the forward EPS is -$7.22.
What is Biora Therapeutics Inc (BIOR) Price-to-Earnings (P/E) ratio?
Biora Therapeutics Inc current P/E ratio is 0.61.
Does Biora Therapeutics Inc (BIOR) pay dividends?
No. Biora Therapeutics Inc does not pay a dividend.
What is Biora Therapeutics Inc (BIOR) beta (volatility) score?
Biora Therapeutics Inc has a beta of 1.276, suggesting it is more volatile than the market.
